CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 38 enrolled
Drug / intervention
Genetic analysisgenetic
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01274065
NCT01274065N/ACompleted
CompareCT.gov

Developing an Interdisciplinary Pharmacogenomic Treatment Approach to Reduce Medication Burden and Improve Subject Outcomes

Avera McKennan Hospital & University Health Center·observational·Posted Jan 11, 2011·Updated Jan 14, 2015

In Brief

An observational study evaluating Genetic analysis for Developmental Disabilities. Completed, enrolled 38 participants.

Detailed Summary

There is no common rule as to how a drug will affect patients. This is due to the effect specific DNA sequences of genes have on drug response, by the effect they have on how medications are metabolized. The primary objective of this research is to optimize medication therapy and to reduce the number of medications used, specifically medications for people with developmental disabilities and co-occuring psychiatric illnesses.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDevelopmental Disabilities
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 11, 2011
Enrollment StartSep 1, 2009
Primary CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 15.5 years ago

Interventions

Genetic analysisgenetic

The research team will review data following DNA sample analysis and identify variants in genes that result in impaired drug metabolism